Average Co-Inventor Count = 3.85
ph-index = 16
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Theravance Biopharma R&d Ip, LLC (74 from 262 patents)
2. Theravance, Inc. (10 from 386 patents)
3. Theravance Respiratory Company, LLC (8 from 12 patents)
92 patents:
1. 12358931 - 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor
2. 12351561 - Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
3. 12016835 - Neprilysin inhibitors
4. 11919888 - Neprilysin inhibitors
5. 11851443 - Neprilysin inhibitors
6. 11718591 - Crystalline (2S,4R)-5-(5'-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof
7. 11718616 - JAK kinase inhibitor compounds for treatment of respiratory disease
8. 11642332 - (2R,4R)-5-(5'-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
9. 11634413 - Neprilysin inhibitors
10. 11547687 - Neprilysin inhibitors
11. 11299492 - JAK kinase inhibitor compounds for treatment of respiratory disease
12. 11261197 - Neprilysin inhibitors
13. 11230536 - Crystalline (2S,4R)-5-(5'-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof
14. 11174219 - Neprilysin inhibitors
15. 11124502 - Neprilysin inhibitors